-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
Evolving Standards of Care
-
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events
Industry Supported
The COCOON trial compared SOC with prophylactic management for treatment-related dermatologic events with amivantamab plus lazertinib. In this Q&A, Dr. Martin F. Dietrich explains the prophylactic regimen’s impact on effects of the skin, scalp, and nails. APP Alyson Singer offers best practices for patient education.
-
Advocate Calls for Stronger Patient Partnerships in Clinical Research
Jane Perlmutter, a survivor of multiple cancers, encouraged investigators to involve patient advocates at every stage of research during the TTLC 2026 Patient Advocate Session.
-
Debate Centers on Whether RAS Inhibitors Will Become First-Line Therapy by 2026
Drs. Ferdinandos Skoulidis and Marina C. Garassino went head-to-head over whether emerging KRAS combination data support first-line adoption by year’s end.
-
Research to Watch: Aumolertinib Delivers Notable Performance as an EGFR-Targeted Therapy in the Adjuvant Setting
Results from the phase III ARTS trial illustrate the potential of aumolertinib as adjuvant therapy for patients with resected EGFR-mutated NSCLC.
-
Stereotactic Radiosurgery for Established Brain Metastases: Prospective Evidence
In the conclusion of this two-part series, Drs. Tomasik and Dziadziuszko highlight unresolved questions and future directions for integrating HA-PCI and SRS into practice for SCLC.
-
Targeting NRG1 Fusions: A Potential Role for Zenocutuzumab as a First-Line Therapeutic Option
Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.
-
National Report Shows Rising Lung Cancer Survival Rates but Gaps in Early Detection
The ALA’s 2025 State of Lung Cancer report highlights survival gains while revealing persistent disparities in diagnosis, treatment, and access to biomarker testing.
-
Modern Brain Radiotherapy in SCLC: Integrating Hippocampal Avoidance and Stereotactic Precision
Drs. Tomasik and Dziadziuszko discuss how the SCLC field is shifting toward brain-sparing techniques to maximize disease control, as well as cognitive preservation.
-
Updated Analysis Confirms Adding Pembrolizumab to Chemotherapy Improves Survival in Mesothelioma
Dr. Scott Laurie recently presented data from IND227 that showed the combination improved overall survival by 24% compared with chemotherapy alone.
-
IASLC Recommendations Define Core Standards for Molecular Tumor Boards
Lead author, Dr. Mihaela Aldea, discusses how the IASLC’s recently published consensus statement could strengthen new and established molecular tumor boards.
-
In Brief for November 19, 2025
The US FDA confirms the use of pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for solid tumor indications.
View ILCN Archives
Provider Resources
Popular Articles